| Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects Y Zhou, M Ingelman‐Sundberg, VM Lauschke Clinical Pharmacology & Therapeutics 102 (4), 688-700, 2017 | 554 | 2017 |
| Integrating rare genetic variants into pharmacogenetic drug response predictions M Ingelman-Sundberg, S Mkrtchian, Y Zhou, VM Lauschke Human genomics 12, 1-12, 2018 | 198 | 2018 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 173 | 2023 |
| Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions SU Vorrink, Y Zhou, M Ingelman-Sundberg, VM Lauschke Toxicological Sciences 163 (2), 655-665, 2018 | 166 | 2018 |
| An optimized prediction framework to assess the functional impact of pharmacogenetic variants Y Zhou, S Mkrtchian, M Kumondai, M Hiratsuka, VM Lauschke The pharmacogenomics journal 19 (2), 115-126, 2019 | 119 | 2019 |
| Comprehensive evaluation of organotypic and microphysiological liver models for prediction of drug-induced liver injury Y Zhou, JX Shen, VM Lauschke Frontiers in pharmacology 10, 473912, 2019 | 109 | 2019 |
| Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity VM Lauschke, Y Zhou, M Ingelman-Sundberg Pharmacology & therapeutics 197, 122-152, 2019 | 91 | 2019 |
| Computational methods for the pharmacogenetic interpretation of next generation sequencing data Y Zhou, K Fujikura, S Mkrtchian, VM Lauschke Frontiers in Pharmacology 9, 417781, 2018 | 57 | 2018 |
| Ethnogeographic and inter-individual variability of human ABC transporters Q Xiao, Y Zhou, VM Lauschke Human Genetics 139 (5), 623-646, 2020 | 43 | 2020 |
| Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost‐Effectiveness of Preemptive Pharmacogenetic Testing Y Zhou, K Krebs, L Milani, VM Lauschke Clinical Pharmacology & Therapeutics 109 (1), 160-174, 2021 | 39 | 2021 |
| The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data Y Zhou, VM Lauschke The Pharmacogenomics Journal 22 (5), 284-293, 2022 | 38 | 2022 |
| Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier Y Zhou, C Dagli Hernandez, VM Lauschke British Journal of Cancer 123 (12), 1782-1789, 2020 | 30 | 2020 |
| Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk [S] Y Zhou, R Mägi, L Milani, VM Lauschke Journal of lipid research 59 (10), 1987-2000, 2018 | 29 | 2018 |
| Pharmacogenomics in the era of next generation sequencing–from byte to bedside LE Russell, Y Zhou, AA Almousa, JK Sodhi, CK Nwabufo, VM Lauschke Drug Metabolism Reviews 53 (2), 253-278, 2021 | 26 | 2021 |
| Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health Y Zhou, VM Lauschke Human Genetics 141 (6), 1113-1136, 2022 | 25 | 2022 |
| Organotypic and microphysiological human tissue models for drug discovery and development—current state-of-the-art and future perspectives S Youhanna, AM Kemas, L Preiss, Y Zhou, JX Shen, SD Cakal, ... Pharmacological Reviews 74 (1), 141-206, 2022 | 25 | 2022 |
| Germline variant burden in multidrug resistance transporters is a therapy‐specific predictor of survival in breast cancer patients Q Xiao, Y Zhou, S Winter, F Buettner, E Schaeffeler, M Schwab, ... International Journal of Cancer 146 (9), 2475-2487, 2020 | 24 | 2020 |
| Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews Y Zhou, VM Lauschke Journal of Medical Genetics 55 (9), 617-627, 2018 | 24 | 2018 |
| Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine Y Zhou, GH Arribas, A Turku, T Jürgenson, S Mkrtchian, K Krebs, Y Wang, ... Science Advances 7 (36), eabi6856, 2021 | 21 | 2021 |
| Computational tools to assess the functional consequences of rare and noncoding pharmacogenetic variability Y Zhou, VM Lauschke Clinical Pharmacology & Therapeutics 110 (3), 626-636, 2021 | 21 | 2021 |
Volker LauschkeFull Professor, Karolinska Institutet; Deputy Head, IKPVerified email at ki.se
